Filing Flows › Health Care › China Pharma Holdings (CPHI)
China Pharma Holdings (CPHI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · China Pharma Holdings (CPHI) Q2 2026 earnings results →
Q2 2026 Revenue down 8% year over year to $948K · 154¢ of every $1 of revenue lost · operating margin -151.0%
China Pharma Holdings made $948K in Q2 2026 (-8% Y/Y). Operating margin -151.0%, net loss $1.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $948K in Q2 2026, down 8% year over year and down 4% from the previous quarter.
Gross margin was 8.8%. Operating costs exceeded revenue by $1.4M, an operating margin of -151.0%. The fastest-growing cost line was General & admin (+212%). The quarter ended with a net loss of $1.5M, wider than the previous quarter's $1.1M loss.
Operating cash flow was −$33K. Non-cash charges added back $1.1M of depreciation and amortization. Working capital and other items added $323K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $948K | -8% | -151.0% | −$1.5M | −$33K |
| Q1 2026 | 10-Q | May 15, 2026 | $984K | -13% | -113.6% | −$1.1M | −$55K |
| Q4 2025 | 10-K | Apr 1, 2026 | $1.2M | +8% | -97.9% | −$1.2M | $152K |
| Q3 2025 | 10-Q | Nov 12, 2025 | $756K | -31% | -83.1% | −$651K | −$237K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.0M | +11% | -63.6% | −$528K | $291K |
| Q1 2025 | 10-Q | May 14, 2025 | $1.1M | -17% | -66.8% | −$786K | −$58K |
| Q4 2024 | 10-K | Mar 31, 2025 | $1.1M | -47% | -105.5% | −$1.2M | $238K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About China Pharma Holdings
China Pharma Holdings Inc. (the “Company”, “China Pharma”, “we”, “us”, or “our”) is a Nevada holding company. China Pharma is not a Chinese operating company and all the operations are conducted by our wholly owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. (“Helpson”) and Helpson’s subsidiaries in China. We, through Helpson, are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People’s Republic of China (the “PRC”). All of the operations are conducted in the PRC, where the manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
In its own words, from its 10-K, filed Apr 1, 2026.
China Pharma Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -8% against the peers' median +7%. Operating margin: -151.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CPHI China Pharma Holdings | Q2 2026 | $948K | -8% | -151.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: China Pharma Holdings 10-Q on SEC EDGAR · CIK 1106644 · Pharmaceutical Preparations
13F: who owns CPHI and who is buying
More on CPHI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results